Clinical trial of meloxicam combined with glucosamine sulfate in the treatment of patients with osteoarthritis
10.13699/j.cnki.1001-6821.2018.10.006
- VernacularTitle:美洛昔康联合硫酸氨基葡萄糖治疗骨关节炎的临床研究
- Author:
Hong-De HAN
1
;
Jia-Zheng JIANG
;
Heng-Lin ZHANG
;
Long SANG
;
Gui-Bin HAN
Author Information
1. 儋州市第一人民医院骨科
- Keywords:
meloxicam;
glucosamine sulfate;
osteoarthritis
- From:
The Chinese Journal of Clinical Pharmacology
2018;34(10):1151-1154
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of meloxicam combined with glucosamine sulfate in the treatment of patients with osteoarthritis.Methods Ninety cases of knee osteoarthritis were randomly divided into control group and treatment group,each group 45 cases.Control group was given meloxicam tablets 7.5 mg,bid,oral.On the basis of control group,treatment group was treated with glucosamine sulfate capsules 0.5 g,tid,oral.All the patients were treated for 6 weeks.The clinical symptoms,signs,knee joint motor function and pain indexes of all patients were evaluated before and after treatment.The blood samples and joint fluid specimens were collected,to determine the matrix metalloproteinase-3 (MMP-3),matrix metalloproteinase-13 (MMP-13) and prostaglandin E2 (PGE2) levels by enzyme linked immunosorbent assay (ELISA).The clinical efficacy and adverse drug reactions in two groups were compared.Results After treatment,the levels of Lequesne indexes in treatment group and control group were 5.78 ± 3..04 and 8.24 ± 3.62,Lysholm scores were 85.82 ± 10.01 and 72.46 ± 13.58,VAS scores were 2.45 ± 1.08 and 3.86 ± 1.17,serum MMP-3 levels were (114.69 ± 13.54) and (130.52 ± 16.48) ng · L-1,serum MMP-13 levels were (141.06 ± 21.55) and (179.82 ± 24.37) ng · L-1,serum PGE2 levels were(69.82 ± 18.67)and(91.30 ±20.09)ng · L-1,joint fluid MMP-3 levels were(17.89 ±5.12) and (23.10 ±5.46)ng · L-1,joint fluid MMP-13 levels were(27.35 ±6.52)and(38.47 ±6.85)ng · L-1,joint fluid PGE2 levels were (82.16 ± 22.64) and (118.02 ± 23.41) ng · L-1,all with significant difference (all P ＜ 0.05).The improvement rates of control group and treatment group were 73.33％ (33 cases/45 cases),91.11％ (41 cases/45 case),with significant difference (P ＜ 0.05).No adverse drug reactions occurred during the treatment.Conclusion The clinical effect of meloxicam combined with glucosamine sulfate in the treatment of knee osteoarthritis is exact,the treatment is conducive to the improvement of clinical symptoms,can reduce serum MMP-3,MMP-13,PGE2 levels,with high safety.
